

UC Berkeley

UC Berkeley Previously Published Works

Title

Telomeric replication stress: the beginning and the end for alternative lengthening of telomeres cancers.

Permalink

<https://escholarship.org/uc/item/33t380x1>

Journal

Open Biology, 12(3)

Authors

Lu, Robert

Pickett, Hilda

Publication Date

2022-03-01

DOI

10.1098/rsob.220011

Peer reviewed

Review



Cite this article: Lu R, Pickett HA. 2022
Telomeric replication stress: the beginning and
the end for alternative lengthening of
telomeres cancers. *Open Biol.* **12:** 220011.
<https://doi.org/10.1098/rsob.220011>

Received: 14 January 2022

Accepted: 9 February 2022

Subject Area:

molecular biology/cellular biology/genomics

Keywords:

telomere maintenance, replication stress,
alternative lengthening of telomeres, ALT

Author for correspondence:

Hilda A. Pickett

e-mail: hpickett@cmri.org.au

Telomeric replication stress: the beginning and the end for alternative lengthening of telomeres cancers

Robert Lu and Hilda A. Pickett

Telomere Length Regulation Unit, Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia

HAP, 0000-0002-9840-4841

Telomeres are nucleoprotein structures that cap the ends of linear chromosomes. Telomeric DNA comprises terminal tracts of G-rich tandem repeats, which are inherently difficult for the replication machinery to navigate. Structural aberrations that promote activation of the alternative lengthening of telomeres (ALT) pathway of telomere maintenance exacerbate replication stress at ALT telomeres, driving fork stalling and fork collapse. This form of telomeric DNA damage perpetuates recombination-mediated repair pathways and break-induced telomere synthesis. The relationship between replication stress and DNA repair is tightly coordinated for the purpose of regulating telomere length in ALT cells, but has been shown to be experimentally manipulatable. This raises the intriguing possibility that induction of replication stress can be used as a means to cause toxic levels of DNA damage at ALT telomeres, thereby selectively disrupting the viability of ALT cancers.

1. Introduction

Telomeres are evolutionarily conserved G-rich sequences at the distal ends of linear chromosomes. In humans, telomeres consist of tandem arrays of (TTAGGG)_n repeats that are typically 4–8 kb in length and terminate in a 100–300 base pair single-stranded (ss) G-rich 3' overhang [1–4]. The telomere overhang is able to loop back on itself and strand-invade upstream repeats on the same telomere to form a lariat structure called a telomere-loop (t-loop) [5–7]. Telomeric DNA is bound by the shelterin protein complex, which comprises TRF1, TRF2, RAP1, TIN2, TPP1 and POT1 [8–10], and it is this telomeric DNA and shelterin nucleoprotein structure that protects the ends of the chromosomes from being recognized as sites of DNA damage. Shelterin fulfils a specialized role in the maintenance of telomere integrity and is vital for the fidelity of telomere replication, telomeric transcription and coordinating the deposition of heterochromatic nucleosomes at telomeres [11–17].

Telomere length shortens with cellular division and negatively correlates with chronological age due to limitations in the ability of the replication machinery to fully replicate the linear DNA molecule [18–23]. Telomere shortening eventually results in telomere dysfunction, which is attributed to inadequate shelterin binding and the inability to form a t-loop, and culminates in cellular senescence or apoptosis [6]. These proliferative barriers can be overcome by stabilization of the genome through activation of a telomere maintenance mechanism (TMM). Telomere maintenance is a hallmark of cancer cells and is essential for replicative immortality [24]. Cancer cells typically activate either the ribonucleoprotein enzyme telomerase, or the alternative lengthening of telomeres (ALT) pathway. Importantly, most normal human somatic cells lack a TMM [25].

Telomeres present an exceptional challenge to the replication machinery. This is the cumulative result of the terminal repetitive G-rich sequence content of telomeres, the necessity for constant structural remodelling of telomeric DNA into t-loops, displacement loops (D-loops), DNA/RNA hybrids and G-quadruplex structures during replication and transcription, the constitutive heterochromatic organization of telomeric chromatin, and the engagement of opposing telomere length regulation mechanisms. This is further compounded by a reliance on subtelomeric origins of replication. The replication challenge is heightened at ALT telomeres, with ALT cells displaying exacerbated levels of telomere replication stress that functionally perpetuate telomere extension. In this review, we discuss telomeric replication, the homeostasis between replication stress and repair at ALT telomeres, and how tipping this balance can impact ALT activity and ALT cell viability.

2. Telomere replication

DNA replication is a spatially and temporally regulated process that commences in late mitosis and G1 with replication origin licensing, followed by origin activation at the G1–S transition, and origin firing in S-phase [26]. The origin recognition complex (ORC) loads minichromosome maintenance replicative helicase complex (MCM2-7) onto origins [27,28], enabling replication forks to travel in opposite directions from the origin of replication. Some origins remain dormant, with the opportunity to become activated in response to localized fork stalling. Mammalian telomeres, unlike yeast telomeres, are replicated throughout S-phase and lack a consensus replication origin sequence [29]. Telomere replication predominantly originates from subtelomeric regions, with the replisome travelling through the telomeres in a unidirectional manner [13,30]. More recently, it has been revealed that the shelterin component TRF2 can recruit ORC proteins to facilitate replication of telomeres [31,32]. These events are, however, relatively rare and appear to become activated in situations of replication stress as a rescue mechanism to complete telomere replication [13]. The paucity of origins within telomeres means that if a telomeric replication fork encounters a problem, it is unlikely to be rescued by a converging distal fork travelling in the opposite direction. This results in a heightened reliance on fork repair and restart mechanisms at telomeres.

In addition to the lack of replication origins within telomeres, replication of the ends of linear DNA molecules is problematic due to limitations in accessibility by the replication machinery. Specifically, progression of the replication fork requires the coordination of both continuous leading-strand and discontinuous lagging-strand synthesis at the replication fork, the bulk of which is performed by DNA polymerases ϵ and δ [33–35]. The ends of the Okazaki fragments produced by lagging-strand synthesis are then processed to remove the RNA primer and ligated together to form a continuous strand. When the replication machinery reaches the end of the chromosome, positioning of the last Okazaki fragment approximately 70 bp upstream on the lagging-strand leads to an inability to completely replicate the lagging-strand template, a limitation known as the end-replication problem [36]. This results in a gradual loss of telomeric sequences with each round of DNA replication and cell division. Additional post-replicative nucleolytic

processing of the telomere 3'-overhang by Apollo, ExoI and other factors also contributes to telomere attrition [37–40].

3. Telomeres are prone to replication stress

Inherent limitations of the replication machinery are compounded by the structural features of telomeres that make them prone to replication stress. Replication stress refers to a slowing or stalling of the replication machinery and occurs when one of the DNA polymerases encounters either a block on the template DNA, or chemical interference such as nucleotide pool depletion or polymerase inhibition [41]. The cellular response to replication stress is orchestrated by the ATR–CHK1 kinase pathway [42]. Telomeres are particularly susceptible to replication stress due to their terminal location, G-rich repetitive sequence content, heterochromatic conformation and the low distribution of telomeric origins [26,43–45]. D-loop and t-loop structures must be unwound to enable replication fork progression. In addition, the G-rich telomeric strand has a high propensity to form four-stranded G-quadruplex structures [46,47]. Removal of G-quadruplexes and unwinding of the t-loop are essential to prevent fork stalling and telomere loss during replication (figure 1). This is performed non-redundantly by several helicases that recognize and unwind G-quadruplexes, including BLM, WRN and RTEL1, FANCD1 and ATRX [48,49]. The G-rich strand can also accumulate 8-oxo-G oxidative lesions, which can result in replication defects and telomere loss (figure 1) [50–53].

Transcription–replication conflicts also contribute to replication stress. Telomeric repeat-containing long noncoding RNA, or TERRA, which comprises UUAGGG repeats transcribed terminally from the subtelomere, can form RNA–DNA hybrids and R-loops at telomeres (figure 1) [54]. These hybrid molecules are regulated by RNase-H and several DNA/RNA-helicases, including RTEL1, FANCD1, PIF1, as well as the mRNA-transcription export machinery [55–60].

Replication stress is associated with late replication that persists through G2-phase into mitosis, and manifests as mitotic DNA synthesis (MiDAS) [61–63]. Telomeric MiDAS can be induced using a variety of replication blocking agents, including aphidicolin, which inhibits DNA polymerase α , and G-quadruplex stabilizing ligands such as PhenDC3, TmPyP4 and Pyridostatin [64–66]. These obstacles highlight the importance of helicases, endonucleases and homology-directed repair factors for telomere replication. Telomeric MiDAS is typically observed on metaphase spreads after nucleoside labelling during mitotic release from G2 arrest [63]. Specifically, it is visualized as telomere synthesis occurring on a single chromatid arm and is indicative of conservative DNA synthesis resulting from a telomere DNA double-strand break (DSB) caused by a collapsed replication fork [67]. Most repair factors required for genomic MiDAS, such as POLD, BLM and RAD52, are also required for telomeric MiDAS, with the exception of MUS81 [61,62,68,69].

4. Shelterin protects telomeres from replication stress

Despite these limitations, telomeres are successfully replicated each time a cell divides. This can be predominantly




Figure 1. Sources of replication stress at ALT telomeres and key factors that prevent replication fork collapse. Replication stress is exacerbated at ALT telomeres by the loss of ATRX/DAXX function, associated aberrant H3.3 heterochromatin deposition, telomeric R-loops, 8-oxo-G (8-oxo-guanine) lesions and G-quadruplex accumulation, and the interspersions of variant telomere repeats that displace shelterin binding and promote recombination. FANCM and its associated binding partners MHF1/2 and FAAP24, and the FA core complex component FANCF, as well as the SMARCAL1 fork translocase and ATR kinase, protect ALT telomeres from excessive replication stress that can lead to fork collapse. This can then lead to a DNA-damage response typified by accumulation of replication protein A (RPA) and phosphorylated histone variant H2AX (γ -H2AX).

attributed to shelterin, which binds specifically to the telomere sequence and structure, coordinating the recruitment of proteins that maintain replication fidelity. TRF1 and TRF2 display high-affinity binding to double-stranded telomeric DNA through their Myb/SANT domains, while POT1 binds to single-stranded telomeric DNA through its oligonucleotide/oligosaccharide-binding folds [10,70,71]. TRF2 is also capable of binding to branched DNA structures through its N-terminal basic domain [72–74]. In this capacity, shelterin facilitates generation of the 3' overhang and formation of the t-loop structure, which is stabilized when the 3' terminus of the telomere is sequestered in a D-loop [6,7,75]. TRF2 also stabilizes and dynamically releases the t-loop structure during replication. This process involves a phospho-switch mechanism that coordinates RTEL1 accessibility during S phase to allow t-loop unwinding and replication, and the release of RTEL1 outside of S phase to enable the t-loop to be restored and maintained [72].

Efficient replication of telomeres is dependent on TRF1, and the absence of TRF1 leads to frequent fork stalling and the appearance of fragile telomeres [76,77]. Fragile telomeres, resulting from replication stress, are often associated with late-replicating intermediates that appear as ultra-fine anaphase bridges. TRF1 also functions to preserve the telomeric chromatin environment by preventing recruitment of homologous recombination factors SMC5/6, BRCA1 and POLD3 that would otherwise promote the engagement of homology-directed repair pathways at the telomeres [78]. Telomere replication navigation further relies on the ability of TRF1 and TRF2 to recruit RTEL1, BLM and WRN helicases to unwind replicative obstacles such as G-quadruplexes

[76,79–83], indicative of the prioritization of mechanisms to avoid telomere replication stress.

5. Telomere maintenance is a replication stress response

Replication-associated telomere shortening can be counteracted by activation of a TMM, and telomere length maintenance can stabilize the genome. Both telomerase and ALT mechanisms respond, and are recruited, to stalled replication forks in telomeres, indicative of telomere maintenance being a form of DNA repair localized to chromosome ends.

Telomerase is a ribonucleoprotein enzyme comprising the hTERT reverse transcriptase and the hTR RNA component that synthesizes telomeric repeats directly onto the chromosome ends. Telomerase is constitutively bound by four H/ACA ribonucleoprotein-binding factors, dyskerin, NOP10, GAR1 and NHP2, and the Cajal Body (CB) chaperone, TCAB1, which collectively confer telomerase complex stability and facilitate enzyme assembly [84–86]. Telomerase is recruited to telomeres during S to late G₂-phase, through a direct interaction between TPP1 and the telomerase essential N-terminal (TEN) domain of hTERT [87–92]. Loss of TRF1 or the presence of stalled forks increases telomerase recruitment to telomeres in an ATR-dependent manner [93]. More recently, it has been shown that telomeric replication stress caused by POT1 dysfunction enables telomeres to travel along nuclear actin filaments to the nuclear periphery, resulting in MiDAS at telomeres in telomerase-positive cells [94,95]. Consistent with replication stress-induced telomere

lengthening, POT1 mutations have been identified in a growing number of cancer types, including chronic lymphocytic leukaemia (CLL), melanoma and sarcoma, and are associated with longer telomere lengths [96]. These discoveries demonstrate the capacity for localized replication stress to promote the repositioning of telomeres and the engagement of telomerase.

ALT is defined as telomere maintenance in the absence of telomerase activity [97,98]. While the precise trigger for ALT activation remains unclear, the underlying pathway of ALT-mediated telomere extension has been well characterized and involves DNA repair synthesis mechanisms that are analogous to break-induced replication [99–101]. Specifically, telomere extension events initiate from DSBs that form from exacerbated and unresolved replication stress and collapsed forks that are particularly prevalent in ALT telomeres. Telomere extension can occur in both G2 and prometaphase, is dependent on the BLM-TOP3A-RMI (BTR) complex and the RFC-PCNA-Pol δ replisome, and proceeds by both RAD52-dependent and RAD52-independent pathways [63,67,102,103]. Paradoxically, aborted telomere crossover events in the absence of telomere synthesis also contribute to the ALT mechanism, and involve the SLX1-SLX4, MUS81-EME1, XPF-ERCC1 (SMX) endonuclease complex [99]. The balance between telomere crossover and non-crossover extension events dictates overall telomere length and the prevalence of the various ALT phenotypic biomarkers, including extrachromosomal telomeric repeats, ALT-associated promyelocytic leukaemia bodies and telomere sister-chromatid exchange (T-SCE) events.

Telomerase and ALT are predominantly activated in a mutually exclusive manner in cancer cells; however, it is unclear when and why activation of one pathway is favoured over the other [104]. Both telomerase and ALT appear to be regulated by telomeric replication stress, but the specific type of replication stress, the nature and magnitude of the response, and the downstream repair pathways that become activated to confer telomere maintenance, are entirely distinct. The involvement of telomere replication stress suggests that telomere maintenance can be regulated by modifying replication stress within telomeres.

6. Cells with alternative lengthening of telomeres display heightened levels of telomeric replication stress

ALT cells display high levels of telomeric DNA damage that arise stochastically as a result of replication stress [15,105]. This is an important and fundamental distinction of ALT telomeres. The underlying reasons for the heightened levels of replication stress at ALT telomeres include interspersed telomeric variant repeats that disrupt the canonical repeat array [106,107], dysregulated telomeric chromatin and an altered nucleoprotein structure resulting from enhanced nuclear receptor binding, reduced shelterin binding and diminished histone levels, all of which exaggerate the inherent problems that normal telomeres present to the replication machinery [108–110].

Telomere variant repeats differ from the canonical TTAGGG sequence at a single nucleotide and include the variants TCAGGG, TGAGGG, TTGGGG and CTAGGG. Variant repeats are enriched in the proximal regions of human

telomeres [111–113]. The mismatch repair machinery functions to minimize recombination events between homeologous sequences by promoting heteroduplex rejection. However, in ALT cells, break-induced telomere synthesis appears to occur to some extent within these proximal degenerate regions and can be dramatically enhanced by deletion of the MutS α mismatch repair complex [114]. This enables the spread and interspersed of variant repeats throughout the telomeres [106,107] and is presumably an inevitable consequence of the exacerbated DNA damage response at ALT telomeres. Variant repeats have a lower binding affinity for TRF2 and preferentially support binding of NR2C/F orphan nuclear receptor proteins, including TR2, TR4, COUP-TF1 and COUP-TF2 [106,108,113,115,116]. A direct correlation between telomere variant repeat content and NR2C/F orphan nuclear receptor binding is lacking. Nevertheless, nuclear receptors are enriched specifically at ALT telomeres and recruit the NuRD-ZNF827 chromatin remodeling complex, which functions both to preserve the telomeric chromatin and to recruit HR proteins. While the precise ramifications of variant repeat interspersed and nuclear receptor binding are unclear, disruption of shelterin binding at ALT telomeres has the potential to promote telomeric replication stress.

Induction of telomere replication stress in ALT cells has further been attributed to loss of function of the ATRX/DAXX chromatin remodelling complex. Loss of function mutations in ATRX or DAXX are the most common genetic feature of ALT cells [117,118]. ATRX is an ATP-dependent helicase and a member of the sucrose non-fermenting (SNF2) family of chromatin remodellers, while DAXX specifically recognizes and loads H3.3 repressive histone variants at telomeres and pericentric heterochromatin in a replication-independent chromatin assembly pathway [119]. ATRX facilitates telomere replication by maintaining the telomeric heterochromatin, and in its absence, secondary structures such as G-quadruplexes persist, promoting replication fork stalling and collapse, and the engagement of break-induced telomere synthesis (figure 1) [120]. ATRX loss also promotes telomere cohesion and compromises cell cycle regulation of TERRA, causing replication protein A (RPA) to persist at telomeric foci after DNA replication [121,122]. While reintroduction of ATRX into ALT cells causes a reduction in replication fork stalling and an overall repression of ALT, loss of ATRX/DAXX is not sufficient to induce ALT, and it remains unclear what additional activating changes are required for ALT [123].

Depletion of the anti-silencing factor 1 (ASF1) paralogues ASF1a and ASF1b that function as histone chaperones for H3.1/H3.3-H4 dimers during nucleosome assembly simultaneously causes rapid induction of ALT phenotypes and repression of hTERT transcription, indicative of defective histone management resulting in replicative stress and ALT engagement [124]. It has previously been shown that ALT telomeric chromatin is less compacted and heterochromatic when compared to telomerase-positive telomeric chromatin [110]. More recently, it has been demonstrated that ALT activity requires a degree of H3K9 trimethylation, mediated by SETDB1, in order to facilitate the recruitment of recombination factors [125]. The reliance of telomeres on SETDB1 histone methyltransferase activity provides a distinction from pericentric heterochromatin, which uses SUV39H for the deposition of H3K9me3 [125].

ALT cells typically display elevated levels of TERRA and abundant telomeric R-loops. It has been proposed that R-loop formation promotes break-induced telomere synthesis at ALT telomeres by exacerbating telomeric replication stress (figure 1) [126]. Overall, ALT telomeres balance high levels of replication stress with homology-directed repair to maintain a structural and functional equilibrium. This poses the question of what happens when this balance is tipped.

7. The cellular implications of replication stress for alternative lengthening of telomeres activity

The implications of replication stress are severe, including DNA damage and genomic instability. The high levels of replication stress at ALT telomeres mean that ALT cells are exquisitely sensitive to further replicative insult or impairment of the replication stress response pathways. This has been comprehensively demonstrated in the context of both FANCM and SMARCAL1 deficiency.

FANCM is an ATPase and DNA translocase that is required for inter-strand cross-link repair, dismantling R-loops and promoting fork restart in response to replication stress [127–129]. FANCM contains a DEAD/DEAH helicase ATPase domain with translocase activity, an expanded C-terminal region that includes a C-terminal nuclease-dead endonuclease ERCC4-like domain and an expanded middle disordered region comprising the MM1 domain that interacts with the Fanconi Anaemia (FA) core complex and the MM2 domain that interacts with the BLM-TOP3A-RMI (BTR) complex [130,131]. FANCM acts as a platform for the assembly of the FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FAAP20 and FAAP100), which monoubiquitinates the FANCI/FANCD2 heterodimer. Monoubiquitinated FANCD2 then localizes to stalled forks and stabilizes FANCI/FANCD2 heterodimers on dsDNA to unhook the stalled fork and promote homologous recombination and lesion bypass [128,132–138].

It was first reported that depletion of FANCM reduces replication efficiency and induces telomeric replication stress in ALT cells [139]. Subsequent studies by three separate laboratories demonstrated that FANCM depletion causes exacerbated levels of telomere replication stress and damage, activation of ATR signalling and a hyper-ALT phenotype [56,59,139,140]. These outcomes caused a G2 cell cycle arrest and were selectively toxic to ALT cells. The ATPase/translocase activity of FANCM and the interaction between FANCM and the BLM-TOP3A-RMI (BTR) complex, which facilitates replication fork remodelling, were both required to attenuate replication stress at ALT telomeres [56,59,140]. This is indicative of persistent R-loops and unresolved replication stress or fork collapse reaching levels that are ultimately catastrophic to ALT cells (figure 1).

SMARCAL1 is an ATP-dependent annealing helicase that interacts with RPA and functions to stabilize replication forks during DNA damage. SMARCAL1, but interestingly not related SNF2 family members HLTF or ZRANB3, plays a key role in mitigating replication stress at ALT telomeres [141]. Specifically, SMARCAL1 depletion causes stalled

replication forks to deteriorate to form DSBs, saturating the capabilities of the DNA repair machinery, resulting in chromosomal fusions and thereby driving genomic instability [142,143].

While both FANCM and SMARCAL1 fork translocases exhibit fork remodelling and branch migration activities, the overall magnitude of phenotypic changes observed following FANCM depletion is considerably greater than for SMARCAL1 depletion. This is likely indicative of FANCM being the principal fork translocase required to prevent fork collapse at distally progressing replication forks in ALT telomeres [30,141]. SMARCAL1 is also less capable of remodelling a replication fork when there is RPA accumulation on the lagging strand, which may further explain the more critical role for FANCM at ALT telomeres (figure 1) [144].

8. Replication stress modifiers as novel therapeutic targets for alternative lengthening of telomeres cancers

More expansive evidence for the hypersensitivity of ALT cells to replication stress comes from Project Achilles hosted on the Cancer Dependency Map Portal (DepMap Public 21Q3). Project Achilles provides unbiased gene essentiality data derived from genome-wide RNAi and CRISPR/Cas9 loss of function screens performed on over a thousand genomically characterized cancer cell lines. Despite the low prevalence of ALT in this collection of cell lines, and the TMM status of many cell lines remaining unknown, evaluation of ALT-specific gene dependencies demonstrates a clear enrichment of proteins involved in replication fork remodelling and the replication stress response (figure 2*a*). Preferentially essential genes were identified by the average gene essentiality score of eight validated and fully characterized ALT cell lines and were then compared to the average gene essentiality score of all remaining cell lines, the majority of which will be telomerase-positive. FANCM had the top dependency score, being the clear outlier and the major essential gene across all identified ALT cell lines. This demonstrates encouraging convergence between unbiased screening approaches and discovery science in uncovering new and specific cancer dependencies.

FANCM obligate binding partners MHF1/2 (CENPS/CENPX) and FAAP24, which localize FANCM to DNA [59,145], were also enriched in the top 14 preferentially essential genes for ALT (figure 2*b*). Other ALT-dependent genes included FANCF, a key subunit of the FA core complex that interacts directly with FANCM [132], SMARCAL1 and ATR. Overall, this supports the rationale that ALT cells depend on FANCM and, to a lesser degree, the FA pathway, SMARCAL1 and ATR to manage telomeric replication stress, and that deletion or disruption of these proteins is toxic to ALT cells (figures 1 and 2). Several other potential ALT-specific gene dependencies were uncovered, with less explicit roles in replication stress, including ITGAV (Integrin receptor alpha V) and FGFR (fibroblast growth factor receptor 1), which are commonly activated or overexpressed in cancers; GPX4 (glutathione peroxidase 4), which protects cells from membrane lipid peroxidation; NRDE2, which functions in RNA splicing and export; SUB1, a transcriptional co-activator of RNA pol II that has a role in avoiding G4-induced




Figure 2. Top 14 gene dependency scores for known ALT cell lines. (a) Top 14 ranked adjusted gene essentiality scores from $n = 17394$ genes of eight known ALT cell lines (G-292, HS729, SK-N-FI, U-2 OS, Saos-2, CAL78, Hu09 and CAL72). Adjusted gene scores were calculated from the average gene essentiality score of the eight ALT cell lines minus the average gene essentiality score of all remaining cell lines from the Project Achilles dataset ($n = 1024$, DepMap Public 21Q3). (b) Non-adjusted gene essentiality scores (CERES) of each of the eight known ALT cell lines, average CERES scores of all eight ALT cell lines (average ALT) and average CERES scores of all remaining cell lines (average remaining) from the Project Achilles dataset (see <https://doi.org/10.6084/m9.figshare.15160110.v2>, DepMap 21Q3 Public).

transcriptional damage; and PPP1CB (protein phosphatase 1 catalytic subunit beta) and CCNA2 (Cyclin A2), which are involved in cell cycle progression [146–154]. These data and further analysis and extrapolation of similar resources provide insights into the genes and pathways that are necessary for ALT cancer survival.

The strong biological foundation that supports induction of telomere-specific replication stress as a rapid and potent means to destroy ALT cancer cells implicates proteins such as FANCM and SMARCAL1 as potential targets for the development of ALT therapeutics. Proof of concept for this approach has involved synthetic inhibition of FANCM–BTR complex formation using both a competitive peptide and a small molecule inhibitor [140,145]. Efforts to disrupt the FANCM–BTR interaction as a means to inhibit ALT cancer cell growth are preliminary, but the strategy appears promising. Other functional domains on FANCM may also prove to be viable targets for drug development, for instance the protein–protein interactions between FANCM and FAAP24 and FANCM and MHF1/MHF2, both of which are supported by compelling gene dependency data from Project Achilles, and the ATPase/translocase domain of FANCM [56,59,140,145]. SMARCAL1 may also be a viable therapeutic target, potentially through its HARP or ATPase domains [141]. Other proteins with specific functions in managing telomere replication stress may also emerge as our understanding of the ALT mechanism matures.

9. Conclusion

Cancers that rely on the ALT pathway of telomere maintenance constitute approximately 10–15% of all cancers, with this proportion rising substantially in tumours of mesenchymal and neuroepithelial origin [155]. Although ALT cancers are typically aggressive with poor prognosis, ALT status is not yet considered in cancer diagnosis, with no specific

treatments currently available for ALT cancers. Cancers that use the ALT pathway have an intrinsic reliance on replication stress to direct DNA repair pathways to the telomeres to achieve homology-directed telomere extension. This reliance confers a heightened sensitivity to the disruption of factors that regulate telomere replication stress in ALT cells. Parallel hypothesis-driven molecular studies and unbiased knockout screens have identified FANCM and SMARCAL1 as key proteins required for ALT cell viability, with specific roles in managing replication stress at ALT telomeres. Furthermore, the disruption of FANCM function using a small molecule inhibitor has been shown to be selectively detrimental to ALT cancer cells. Despite the strong molecular foundation for the manipulation of replication stress at ALT telomeres having therapeutic potential, substantial effort is required to further develop these discoveries.

Adopting a strategy of catastrophic telomere replication stress induction as a means to destroy ALT cancer cells has obvious pitfalls. As break-induced telomere synthesis events in ALT cells emanate from the deterioration of stalled replication forks, there is a clear risk that exacerbated telomere replication stress will fail to hit toxic levels and will instead promote ALT activity, essentially stoking the fire in an already aggressive tumour environment. Encouragingly, this does not appear to be the case for FANCM inhibition, with cell toxicity occurring rapidly and broadly. Nevertheless, this is an important consideration for future ALT therapeutics. As the potential for ALT targeted cancer therapeutics develops, understanding the origin and type of replication stress that underlies ALT activity, the host of proteins that manage this replication stress, and the toxic outcomes of fork stalling and collapse all require further attention.

Data accessibility. The gene dependency score dataset used in this publication is available at <https://depmap.org/portal/download/all/>. <https://doi.org/10.6084/m9.figshare.15160110.v2>.

The DepMap Public 21 dataset used for figure 2 is accessible at <https://depmap.org/portal/download/>.

Authors' contributions. R.L.: writing—original draft and writing—review and editing; H.A.P.: conceptualization, writing—original draft and writing—review and editing. Both authors gave final approval for publication and agreed to be held accountable for the work performed therein.

Competing interests. H.A.P. is a co-founder and shareholder of Tessellate Bio.

Funding. This work is supported by the Australian Medical Research Future Fund (grant no. 2007488).

Acknowledgements. We thank Alexander Sobinoff and Jixuan Gao for critical reading of the manuscript.

References

- Meyne J, Ratliff RL, Moyzis RK. 1989 Conservation of the human telomere sequence (TTAGGG)_n among vertebrates. *Proc. Natl Acad. Sci. USA* **86**, 7049–7053. (doi:10.1073/pnas.86.18.7049)
- Makarov VL, Hirose Y, Langmore JP. 1997 Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. *Cell* **88**, 657–666. (doi:10.1016/s0092-8674(00)81908-x)
- Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. 1997 Normal human chromosomes have long G-rich telomeric overhangs at one end. *Gene Dev.* **11**, 2801–2809. (doi:10.1101/gad.11.21.2801)
- Larrivée M, LeBel C, Wellinger RJ. 2004 The generation of proper constitutive G-tails on yeast telomeres is dependent on the MRX complex. *Gene Dev.* **18**, 1391–1396. (doi:10.1101/gad.1199404)
- Doksani Y, Wu JY, de Lange T, Zhuang X. 2013 Super-resolution fluorescence imaging of telomeres reveals TRF2-dependent T-loop formation. *Cell* **155**, 345–356. (doi:10.1016/j.cell.2013.09.048)
- Van Ly D, Low RRR, Frolich S, Bartolec TK, Kafer GR, Pickett HA, Gaus K, Cesare AJ. 2018 Telomere loop dynamics in chromosome end protection. *Mol. Cell* **71**, 510–525. (doi:10.1016/j.molcel.2018.06.025)
- Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. 1999 Mammalian telomeres end in a large duplex loop. *Cell* **97**, 503–514. (doi:10.1016/s0092-8674(00)80760-6)
- Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P, de Lange T. 1995 A human telomeric protein. *Science* **270**, 1663–1667. (doi:10.1126/science.270.5242.1663)
- de Lange T. 2002 Protection of mammalian telomeres. *Oncogene* **21**, 532–540. (doi:10.1038/sj.onc.1205080)
- de Lange T. 2018 Shelterin-mediated telomere protection. *Annu. Rev. Genet.* **52**, 223–247. (doi:10.1146/annurev-genet-032918-021921)
- Lee YW, Arora R, Wischniewski H, Azzalin CM. 2018 TRF1 participates in chromosome end protection by averting TRF2-dependent telomeric R loops. *Nat. Struct. Mol. Biol.* **25**, 147–153. (doi:10.1038/s41594-017-0021-5)
- Flynn RL, Centore RC, O'Sullivan RJ, Rai R, Tse A, Songyang Z, Chang S, Karlseder J, Zou L. 2011 TERRA and hnRNP1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA. *Nature* **471**, 532–536. (doi:10.1038/nature09772)
- Drosopoulos WC, Deng Z, Twayana S, Kosiyatrakul ST, Vladimirova O, Lieberman PM, Schildkraut CL. 2020 TRF2 mediates replication initiation within human telomeres to prevent telomere dysfunction. *Cell Rep.* **33**, 108379. (doi:10.1016/j.celrep.2020.108379)
- Denchi EL, de Lange T. 2007 Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. *Nature* **448**, 1068–1071. (doi:10.1038/nature06065)
- Cesare AJ, Kaul Z, Cohen SB, Napier CE, Pickett HA, Neumann AA, Reddel RR. 2009 Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. *Nat. Struct. Mol. Biol.* **16**, 1244–1251. (doi:10.1038/nsmb.1725)
- Schoeftner S, Blasco MA. 2010 Chromatin regulation and non-coding RNAs at mammalian telomeres. *Semin. Cell Dev. Biol.* **21**, 186–193. (doi:10.1016/j.semcdb.2009.09.015)
- Dan J *et al.* 2014 *Rif1* maintains telomere length homeostasis of ESCs by mediating heterochromatin silencing. *Dev. Cell* **29**, 7–19. (doi:10.1016/j.devcel.2014.03.004)
- Harley CB, Futcher AB, Greider CW. 1990 Telomeres shorten during ageing of human fibroblasts. *Nature* **345**, 458–460. (doi:10.1038/345458a0)
- Hayflick L. 1965 The limited *in vitro* lifetime of human diploid cell strains. *Exp. Cell Res.* **37**, 614–636. (doi:10.1016/0014-4827(65)90211-9)
- Hayflick L, Moorhead PS. 1961 The serial cultivation of human diploid cell strains. *Exp. Cell Res.* **25**, 585–621. (doi:10.1016/0014-4827(61)90192-6)
- Takubo K *et al.* 2000 Telomere shortening with aging in human liver. *J. Gerontol. A Biol. Sci. Med. Sci.* **55**, B533–B536. (doi:10.1093/gerona/55.11.b533)
- Lingner J, Cooper JP, Cech TR. 1995 Telomerase and DNA end replication: no longer a lagging strand problem? *Science* **269**, 1533–1534. (doi:10.1126/science.7545310)
- Kahl VFS, Allen JAM, Nelson CB, Sobinoff AP, Lee M, Kilo T, Vasireddy RS, Pickett HA. 2020 Telomere length measurement by molecular combing. *Front. Cell Dev. Biol.* **8**, 493. (doi:10.3389/fcell.2020.00493)
- Hanahan D, Weinberg RA. 2011 Hallmarks of cancer: the next generation. *Cell* **144**, 646–674. (doi:10.1016/j.cell.2011.02.013)
- Hiyama E, Hiyama K. 2007 Telomere and telomerase in stem cells. *Br. J. Cancer* **96**, 1020–1024. (doi:10.1038/sj.bjc.6603671)
- Wilhelm T, Said M, Naim V. 2020 DNA replication stress and chromosomal instability: dangerous liaisons. *Genes* **11**, 642. (doi:10.3390/genes11060642)
- Hyrien O. 2015 Peaks cloaked in the mist: the landscape of mammalian replication origins. *J. Cell Biol.* **208**, 147–160. (doi:10.1083/jcb.201407004)
- Urban JM, Foulk MS, Casella C, Gerbi SA. 2015 The hunt for origins of DNA replication in multicellular eukaryotes. *F1000Prime Rep.* **7**, 30. (doi:10.12703/P7-30)
- Higa M, Fujita M, Yoshida K. 2017 DNA replication origins and fork progression at mammalian telomeres. *Genes* **8**, 112. (doi:10.3390/genes8040112)
- Drosopoulos WC, Kosiyatrakul ST, Yan Z, Calderano SG, Schildkraut CL. 2012 Human telomeres replicate using chromosome-specific, rather than universal, replication programs. *J. Cell Biol.* **197**, 253–266. (doi:10.1083/jcb.201112083)
- Higa M, Kushiyama T, Kurashige S, Kohmon D, Enokitani K, Iwahori S, Sugimoto N, Yoshida K, Fujita M. 2017 TRF2 recruits ORC through TRFH domain dimerization. *Biochim. et Biophys. Acta (BBA) Mol. Cell Res.* **1864**, 191–201. (doi:10.1016/j.bbamcr.2016.11.004)
- Tatsumi Y, Ezura K, Yoshida K, Yugawa T, Narisawa-Saito M, Kiyono T, Ohta S, Obuse C, Fujita M. 2008 Involvement of human ORC and TRF2 in pre-replication complex assembly at telomeres. *Genes Cells* **13**, 1045–1059. (doi:10.1111/j.1365-2443.2008.01224.x)
- Burgers PM. 2009 Polymerase dynamics at the eukaryotic DNA replication fork. *J. Biol. Chem.* **284**, 4041–4045. (doi:10.1074/jbc.R800062200)
- Pellegrini L. 2012 The Pol α -primase complex. *Subcellular Biochem.* **62**, 157–169. (doi:10.1007/978-94-007-4572-8_9)
- Tellier-Lebeugue C, Dizet E, Ma E, Veaute X, Coic E, Charbonnier JB, Maloisel L. 2017 The translesion DNA polymerases Pol ζ and Rev1 are activated independently of PCNA ubiquitination upon UV radiation in mutants of DNA polymerase δ . *PLoS Genet.* **13**, e1007119. (doi:10.1371/journal.pgen.1007119)
- Chow TT, Zhao Y, Mak SS, Shay JW, Wright WE. 2012 Early and late steps in telomere overhang processing in normal human cells: the position of the final RNA primer drives telomere shortening. *Gene Dev.* **26**, 1167–1178. (doi:10.1101/gad.187211.112)
- Sfeir AJ, Chai W, Shay JW, Wright WE. 2005 Telomere-end processing the terminal nucleotides of human chromosomes. *Mol. Cell* **18**, 131–138. (doi:10.1016/j.molcel.2005.02.035)
- Wu P, van Overbeek M, Rooney S, de Lange T. 2010 Apollo contributes to G overhang maintenance and

- protects leading-end telomeres. *Mol. Cell* **39**, 606–617. (doi:10.1016/j.molcel.2010.06.031)
39. Wu P, Takai H, de Lange T. 2012 Telomeric 3' overhangs derive from resection by Exo1 and Apollo and fill-in by POT1b-associated CST. *Cell* **150**, 39–52. (doi:10.1016/j.cell.2012.05.026)
 40. Boersma V, Moatti N, Segura-Bayona S, Peuscher MH, van der Torre J, Wevers BA, Orthwein A, Durocher D, Jacobs JLL. 2015 MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5' end resection. *Nature* **521**, 537–540. (doi:10.1038/nature14216)
 41. Shi W *et al.* 2010 The role of RPA2 phosphorylation in homologous recombination in response to replication arrest. *Carcinogenesis* **31**, 994–1002. (doi:10.1093/carcin/bgq035)
 42. Zeman M, Cimprich KA. 2014 Causes and consequences of replication stress. *Nature Cell Biology* **16**, 2–9. (10.1038/ncb2897)
 43. Martinez P, Blasco MA. 2015 Replicating through telomeres: a means to an end. *Trends Biochem. Sci.* **40**, 504–515. (doi:10.1016/j.tibs.2015.06.003)
 44. Huh MS, Ivanochko D, Hashem LE, Curtin M, Delorme M, Goodall E, Yan K, Picketts DJ. 2016 Stalled replication forks within heterochromatin require ATRX for protection. *Cell Death Dis.* **7**, e2220. (doi:10.1038/cddis.2016.121)
 45. Arnoult N *et al.* 2010 Replication timing of human telomeres is chromosome arm-specific, influenced by subtelomeric structures and connected to nuclear localization. *PLoS Genet.* **6**, e1000920. (doi:10.1371/journal.pgen.1000920)
 46. Zhang W, Chen M, Ling Wu Y, Tanaka Y, Juan Ji Y, Lin Zhang S, He Wei C, Xu Y. 2015 Formation and stabilization of the telomeric antiparallel G-quadruplex and inhibition of telomerase by novel benzothioxanthene derivatives with anti-tumor activity. *Sci. Rep.* **5**, 13693. (doi:10.1038/srep13693)
 47. Bochman ML, Paeschke K, Zakian VA. 2012 DNA secondary structures: stability and function of G-quadruplex structures. *Nat. Rev. Genet.* **13**, 770–780. (doi:10.1038/nrg3296)
 48. Sarek G, Vannier JB, Panier S, Petrini JHJ, Boulton SJ. 2015 TRF2 recruits RTEL1 to telomeres in S phase to promote t-loop unwinding. *Mol. Cell* **57**, 622–635. (doi:10.1016/j.molcel.2014.12.024)
 49. Bosch C, Segura-Bayona P, Koole S, van Heteren W, Dewar JT, Tijsterman JM, Knipscheer M. 2014 FANCD1 promotes DNA synthesis through G-quadruplex structures. *EMBO J.* **33**, 2521–2533. (doi:10.15252/emboj.201488663)
 50. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. 2004 Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. *J. Cell Sci.* **117**, 2417–2426. (doi:10.1242/jcs.01097)
 51. Coluzzi E, Colamartino M, Cozzi R, Leone S, Meneghini C, O'Callaghan N, Sgura A. 2014 Oxidative stress induces persistent telomeric DNA damage responsible for nuclear morphology change in mammalian cells. *PLoS ONE* **9**, e110963. (doi:10.1371/journal.pone.0110963)
 52. Barnes RP, Fouquerel E, Opresko PL. 2019 The impact of oxidative DNA damage and stress on telomere homeostasis. *Mech. Ageing Dev.* **177**, 37–45. (doi:10.1016/j.mad.2018.03.013)
 53. Fouquerel E, Barnes RP, Uttam S, Watkins SC, Bruchez MP, Opresko PL. 2019 Targeted and persistent 8-oxoguanine base damage at telomeres promotes telomere loss and crisis. *Mol. Cell* **75**, 117–130. (doi:10.1016/j.molcel.2019.04.024)
 54. Azzalin CM, Reichenbach P, Khoriatou L, Giulotto E, Lingner J. 2007 Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. *Science* **318**, 798–801. (doi:10.1126/science.1147182)
 55. Arora R, Lee Y, Wischniewski H, Brun CM, Schwarz T, Azzalin CM. 2014 RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. *Nat. Commun.* **5**, 5220. (doi:10.1038/ncomms6220)
 56. Pan X *et al.* 2019 FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops. *Sci. Rep.* **9**, 19110. (doi:10.1038/s41598-019-55537-5)
 57. Balk B, Maicher A, Dees M, Klermund J, Luke-Glaser S, Bender K, Luke B. 2013 Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence. *Nat. Struct. Mol. Biol.* **20**, 1199–1205. (doi:10.1038/nsmb.2662)
 58. Azzalin CM, Lingner J. 2015 Telomere functions grounding on TERRA firma. *Trends Cell Biol.* **25**, 29–36. (doi:10.1016/j.tcb.2014.08.007)
 59. Silva B, Pentz R, Figueira AM, Arora R, Lee YW, Hodson C, Wischniewski H, Deans AJ, Azzalin CM. 2019 FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops. *Nat. Commun.* **10**, 2253. (doi:10.1038/s41467-019-10179-z)
 60. Pfeiffer V, Crittin J, Grolimund L, Lingner J. 2013 The THO complex component Thp2 counteracts telomeric R-loops and telomere shortening. *EMBO J.* **32**, 2861–2871. (doi:10.1038/emboj.2013.217)
 61. Bhowmick R, Minocherhomji S, Hickson ID. 2016 RAD52 facilitates mitotic DNA synthesis following replication stress. *Mol. Cell* **64**, 1117–1126. (doi:10.1016/j.molcel.2016.10.037)
 62. Ozer O, Bhowmick R, Liu Y, Hickson ID. 2018 Human cancer cells utilize mitotic DNA synthesis to resist replication stress at telomeres regardless of their telomere maintenance mechanism. *Oncotarget* **9**, 15 836–15 846. (doi:10.18632/oncotarget.24745)
 63. Min J, Wright WE, Shay JW. 2017 Alternative lengthening of telomeres mediated by mitotic DNA synthesis engages break-induced replication processes. *Mol. Cell Biol.* **37**, e00226. (doi:10.1128/mcb.00226-17)
 64. Berardinelli F, Siteni S, Tanzarella C, Stevens MF, Sgura A, Antocchia A. 2015 The G-quadruplex-stabilising agent RHP54 induces telomeric dysfunction and enhances radiosensitivity in glioblastoma cells. *DNA Repair* **25**, 104–115. (doi:10.1016/j.dnarep.2014.10.009)
 65. Muller S, Sanders DA, Di Antonio M, Matis S, Riou JF, Rodriguez R, Balasubramanian S. 2012 Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells. *Org. Biomol. Chem.* **10**, 6537–6546. (doi:10.1039/c2ob25830g)
 66. Kim MY, Gleason-Guzman M, Izbicka E, Nishioka D, Hurley LH. 2003 The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. *Cancer Res.* **63**, 3247–3256.
 67. Roumelioti FM, Sotiriou SK, Katsini V, Chiourea M, Halazonetis TD, Gagos S. 2016 Alternative lengthening of human telomeres is a conservative DNA replication process with features of break-induced replication. *EMBO Rep.* **17**, 1731–1737. (doi:10.15252/embr.201643169)
 68. Min J, Wright WE, Shay JW. 2019 Clustered telomeres in phase-separated nuclear condensates engage mitotic DNA synthesis through BLM and RAD52. *Gene Dev.* **33**, 814–827. (doi:10.1101/gad.324905.119)
 69. Fugger K, Chu WK, Haahr P, Kousholt AN, Beck H, Payne MJ, Hanada K, Hickson ID, Sorensen CS. 2013 FBH1 co-operates with MUS81 in inducing DNA double-strand breaks and cell death following replication stress. *Nat. Commun.* **4**, 1423. (doi:10.1038/ncomms2395)
 70. Kratz K, de Lange T. 2018 Protection of telomeres 1 proteins POT1a and POT1b can repress ATR signaling by RPA exclusion, but binding to CST limits ATR repression by POT1b. *J. Biol. Chem.* **293**, 14 384–14 392. (doi:10.1074/jbc.RA118.004598)
 71. Palm W, de Lange T. 2008 How shelterin protects mammalian telomeres. *Annu. Rev. Genet.* **42**, 301–334. (doi:10.1146/annurev.genet.41.110306.130350)
 72. Sarek G *et al.* 2019 CDK phosphorylation of TRF2 controls t-loop dynamics during the cell cycle. *Nature* **575**, 523–527. (doi:10.1038/s41586-019-1744-8)
 73. Poulet A *et al.* 2009 TRF2 promotes, remodels and protects telomeric Holliday junctions. *EMBO J.* **28**, 641–651. (doi:10.1038/emboj.2009.111)
 74. Schmutz I, Timashev L, Xie W, Patel DJ, de Lange T. 2017 TRF2 binds branched DNA to safeguard telomere integrity. *Nat. Struct. Mol. Biol.* **24**, 734–742. (doi:10.1038/nsmb.3451)
 75. Stansel RM, de Lange T, Griffith JD. 2001 T-loop assembly *in vitro* involves binding of TRF2 near the 3' telomeric overhang. *EMBO J.* **20**, 5532–5540. (doi:10.1093/emboj/20.19.5532)
 76. Sfeir A, Kosiyatrakul ST, Hockemeyer D, MacRae SL, Karlseder J, Schildkraut CL, de Lange T. 2009 Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. *Cell* **138**, 90–103. (doi:10.1016/j.cell.2009.06.021)
 77. Martinez P *et al.* 2009 Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. *Gene Dev.* **23**, 2060–2075. (doi:10.1101/gad.543509)
 78. Porreca RM, Herrera-Moyano E, Skourti E, Law PP, Gonzalez Franco R, Montoya A, Faull P, Kramer H, Vannier JB. 2020 TRF1 averts chromatin remodelling, recombination and replication dependent-break induced replication at mouse

- telomeres. *eLife* **9**, e49817. (doi:10.7554/eLife.49817)
79. Li JL, Harrison RJ, Reszka AP, Brosh Jr RM, Bohr VA, Neidle S, Hickson ID. 2001 Inhibition of the Bloom's and Werner's syndrome helicases by G-quadruplex interacting ligands. *Biochemistry* **40**, 15 194–15 202. (doi:10.1021/bi011067h)
 80. Crabbe L, Verdun RE, Haggblom CI, Karlseder J. 2004 Defective telomere lagging strand synthesis in cells lacking WRN helicase activity. *Science* **306**, 1951–1953. (doi:10.1126/science.1103619)
 81. Sidorova JM, Kehrl K, Mao F, Monnat Jr R. 2013 Distinct functions of human RECQ helicases WRN and BLM in replication fork recovery and progression after hydroxyurea-induced stalling. *DNA Repair* **12**, 128–139. (doi:10.1016/j.dnarep.2012.11.005)
 82. Machwe A, Xiao L, Orren DK. 2004 TRF2 recruits the Werner syndrome (WRN) exonuclease for processing of telomeric DNA. *Oncogene* **23**, 149–156. (doi:10.1038/sj.onc.1206906)
 83. Zimmermann M, Kibe T, Kabir S, de Lange T. 2014 TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling. *Gene Dev.* **28**, 2477–2491. (doi:10.1101/gad.251611.114)
 84. Vulliamy T, Beswick R, Kirwan M, Marrone A, Digweed M, Walne A, Dokal I. 2008 Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. *Proc. Natl Acad. Sci. USA* **105**, 8073–8078. (doi:10.1073/pnas.0800042105)
 85. Pogacic V, Dragon F, Filipowicz W. 2000 Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10. *Mol. Cell Biol.* **20**, 9028–9040. (doi:10.1128/mcb.20.23.9028-9040.2000)
 86. Cerone MA, Ward RJ, Londono-Vallejo JA, Autexier C. 2005 Telomerase RNA mutated in autosomal dyskeratosis congenita reconstitutes a weakly active telomerase enzyme defective in telomere elongation. *Cell Cycle* **4**, 585–589. (doi:10.4161/cc.4.4.1586)
 87. Zhong FL, Batista LF, Freund A, Pech MF, Venteicher AS, Artandi SE. 2012 TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. *Cell* **150**, 481–494. (doi:10.1016/j.cell.2012.07.012)
 88. Nandakumar J, Bell CF, Weidenfeld I, Zaugg AJ, Leinwand LA, Cech TR. 2012 The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. *Nature* **492**, 285–289. (doi:10.1038/nature11648)
 89. Chen LY, Redon S, Lingner J. 2012 The human CST complex is a terminator of telomerase activity. *Nature* **488**, 540–544. (doi:10.1038/nature11269)
 90. Latrick CM, Cech TR. 2010 POT1–TPP1 enhances telomerase processivity by slowing primer dissociation and aiding translocation. *EMBO J.* **29**, 924–933. (doi:10.1038/emboj.2009.409)
 91. Kelleher C, Kurth I, Lingner J. 2005 Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro. *Mol. Cell Biol.* **25**, 808–818. (doi:10.1128/MCB.25.2.808-818.2005)
 92. Smogorzewska A, de Lange T. 2004 Regulation of telomerase by telomeric proteins. *Annu. Rev. Biochem.* **73**, 177–208. (doi:10.1146/annurev.biochem.73.071403.160049)
 93. Tong AS, Stern JL, Sfeir A, Kartawinata M, de Lange T, Zhu XD, Bryan TM. 2015 ATM and ATR signaling regulate the recruitment of human telomerase to telomeres. *Cell Rep.* **13**, 1633–1646. (doi:10.1016/j.celrep.2015.10.041)
 94. Pinzaru AM *et al.* 2016 Telomere replication stress induced by POT1 inactivation accelerates tumorigenesis. *Cell Rep.* **15**, 2170–2184. (doi:10.1016/j.celrep.2016.05.008)
 95. Pinzaru AM, Kareh M, Lamm N, Lazzarini-Denchi E, Cesare AJ, Sfeir A. 2020 Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore. *Gene Dev.* **34**, 1619–1636. (doi:10.1101/gad.337287.120)
 96. Kim WT *et al.* 2021 Cancer-associated POT1 mutations lead to telomere elongation without induction of a DNA damage response. *EMBO J.* **40**, e107346. (10.15252/embj.2020107346)
 97. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. 1995 Telomere elongation in immortal human cells without detectable telomerase activity. *EMBO J.* **14**, 4240–4248. (doi:10.1002/j.1460-2075.1995.tb00098.x)
 98. Hu Y *et al.* 2016 Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX. *Sci. Rep.* **6**, 32280. (doi:10.1038/srep32280)
 99. Sobinoff AP, Allen JA, Neumann AA, Yang SF, Walsh ME, Henson JD, Reddel RR, Pickett HA. 2017 BLM and SLX4 play opposing roles in recombination-dependent replication at human telomeres. *EMBO J.* **36**, 2907–2919. (doi:10.15252/embj.201796889)
 100. Dilley RL, Verma P, Cho NW, Winters HD, Wondisford AR, Greenberg RA. 2016 Break-induced telomere synthesis underlies alternative telomere maintenance. *Nature* **539**, 54–58. (doi:10.1038/nature20099)
 101. Cho NW, Dilley RL, Lampon MA, Greenberg RA. 2014 Interchromosomal homology searches drive directional ALT telomere movement and synapsis. *Cell* **159**, 108–121. (doi:10.1016/j.cell.2014.08.030)
 102. Verma P, Dilley RL, Zhang T, Gyparaki MT, Li Y, Greenberg RA. 2019 RAD52 and SLX4 act nonepistatically to ensure telomere stability during alternative telomere lengthening. *Gene Dev.* **33**, 221–235. (doi:10.1101/gad.319723.118)
 103. Zhang JM, Yadav T, Ouyang J, Lan L, Zou L. 2019 Alternative lengthening of telomeres through two distinct break-induced replication pathways. *Cell Rep.* **26**, 955–968. (doi:10.1016/j.celrep.2018.12.102)
 104. Heaphy CM *et al.* 2011 Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. *AJPA* **179**, 1608–1615. (doi:10.1016/j.ajpath.2011.06.018)
 105. Hoang SM and O'Sullivan RJ. 2020 Alternative lengthening of telomeres: building bridges to connect chromosome ends. *Trends Cancer* **6**, 247–260. (doi:10.1016/j.trecan.2019.12.009)
 106. Conomos D, Stutz MD, Hills M, Neumann AA, Bryan TM, Reddel RR, Pickett HA. 2012 Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. *J. Cell Biol.* **199**, 893–906. (doi:10.1083/jcb.201207189)
 107. Varley H, Pickett HA, Foxon JL, Reddel RR, Royle NJ. 2002 Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells. *Nat. Genet.* **30**, 301–305. (doi:10.1038/ng834)
 108. DeJardin J, Kingston RE. 2009 Purification of proteins associated with specific genomic loci. *Cell* **136**, 175–186. (doi:10.1016/j.cell.2008.11.045)
 109. Conomos D, Reddel RR, Pickett HA. 2014 NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination. *Nat. Struct. Mol. Biol.* **21**, 760–770. (doi:10.1038/nsmb.2877)
 110. Episkopou H, Draskovic I, Van Beneden A, Tilman G, Mattiussi M, Gobin M, Arnoult N, Londono-Vallejo A, Decottignies A. 2014 Alternative lengthening of telomeres is characterized by reduced compaction of telomeric chromatin. *Nucleic Acids Res.* **42**, 4391–4405. (doi:10.1093/nar/gku114)
 111. Baird DM, Jeffreys AJ, Royle NJ. 1995 Mechanisms underlying telomere repeat turnover, revealed by hypervariable variant repeat distribution patterns in the human Xp/Yp telomere. *EMBO J.* **14**, 5433–5443. (doi:10.1002/j.1460-2075.1995.tb00227.x)
 112. Allshire RC, Dempster M, Hastie ND. 1989 Human telomeres contain at least three types of G-rich repeat distributed non-randomly. *Nucleic Acids Res.* **17**, 4611–4627. (doi:10.1093/nar/17.12.4611)
 113. Lee M, Hills M, Conomos D, Stutz MD, Dagg RA, Lau LM, Reddel RR, Pickett HA. 2014 Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. *Nucleic Acids Res.* **42**, 1733–1746. (doi:10.1093/nar/gkt1117)
 114. Barroso-González J, García-Expósito L, Galaviz P, Lynskey ML, Allen JAM, Hoang S, Watkins SC, Pickett HA, O'Sullivan RJ. 2021 Anti-recombination function of MutS α restricts telomere extension by ALT-associated homology-directed repair. *Cell Rep.* **37**, 110088. (doi:10.1016/j.celrep.2021.110088)
 115. Xu M *et al.* 2019 Nuclear receptors regulate alternative lengthening of telomeres through a novel noncanonical FANCD2 pathway. *Sci. Adv.* **5**, eaax6366. (doi:10.1126/sciadv.aax6366)
 116. Marzec P, Armenise C, Perot G, Roumelioti FM, Basyuk E, Gagos S, Chibon F, DeJardin J. 2015 Nuclear-receptor-mediated telomere insertion leads to genome instability in ALT cancers. *Cell* **160**, 913–927. (doi:10.1016/j.cell.2015.01.044)
 117. Lovejoy CA *et al.* 2012 Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. *PLoS Genet.* **8**, e1002772. (doi:10.1371/journal.pgen.1002772)

118. Bower K, Napier CE, Cole SL, Dagg RA, Lau LM, Duncan EL, Moy EL, Reddel RR. 2012 Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres. *PLoS ONE* **7**, e50062. (doi:10.1371/journal.pone.0050062)
119. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD. 2010 Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. *Proc. Natl Acad. Sci. USA* **107**, 14 075–14 080. (doi:10.1073/pnas.1008850107)
120. Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, Taylor S, Higgs DR, Gibbons RJ. 2015 Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. *Nat. Commun.* **6**, 7538. (doi:10.1038/ncomms8538)
121. Lovejoy CA, Takai K, Huh MS, Picketts DJ, de Lange T. 2020 ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity. *PLoS Biol.* **18**, e3000594. (doi:10.1371/journal.pbio.3000594)
122. Flynn RL *et al.* 2015 Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. *Science* **347**, 273–277. (doi:10.1126/science.1257216)
123. Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA, Reddel RR. 2015 ATRX represses alternative lengthening of telomeres. *Oncotarget* **6**, 16 543–16 558. (doi:10.18632/oncotarget.3846)
124. O'Sullivan RJ, Arnoult N, Lackner DH, Oganessian L, Haggblom C, Corpet A, Almouzni G, Karlseder J. 2014 Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. *Nat. Struct. Mol. Biol.* **21**, 167–174. (doi:10.1038/nsmb.2754)
125. Gauchier M *et al.* 2019 SETDB1-dependent heterochromatin stimulates alternative lengthening of telomeres. *Sci. Adv.* **5**, eaav3673. (doi:10.1126/sciadv.aav3673)
126. Silva B, Arora R, Bione S, Azzalin CM. 2021 TERRA transcription destabilizes telomere integrity to initiate break-induced replication in human ALT cells. *Nat. Commun.* **12**, 3760. (doi:10.1038/s41467-021-24097-6)
127. Blackford AN, Schwab RA, Nieminuszczy J, Deans AJ, West SC, Niedzwiedz W. 2012 The DNA translocase activity of FANCM protects stalled replication forks. *Hum. Mol. Genet.* **21**, 2005–2016. (doi:10.1093/hmg/ddo013)
128. Singh TR *et al.* 2009 Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. *Blood* **114**, 174–180. (doi:10.1182/blood-2009-02-207811)
129. Wang H, Li S, Oaks J, Ren J, Li L, Wu X. 2018 The concerted roles of FANCM and Rad52 in the protection of common fragile sites. *Nat. Commun.* **9**, 2791. (doi:10.1038/s41467-018-05066-y)
130. Zheng X-F, Prakash R, Saro D, Longerich S, Niu H, Sung P. 2011 Processing of DNA structures via DNA unwinding and branch migration by the *S. cerevisiae* Mph1 protein. *DNA Repair.* **10**, 1034–1043. (doi:10.1016/j.dnarep.2011.08.002)
131. Meetei AR *et al.* 2005 A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. *Nat. Genet.* **37**, 958–963. (doi:10.1038/ng1626)
132. Deans AJ, West SC. 2009 FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia. *Mol. Cell* **36**, 943–953. (doi:10.1016/j.molcel.2009.12.006)
133. Xue Y, Li Y, Guo R, Ling C, Wang W. 2008 FANCM of the Fanconi anemia core complex is required for both monoubiquitination and DNA repair. *Hum. Mol. Genet.* **17**, 1641–1652. (doi:10.1093/hmg/ddn054)
134. Medhurst AL *et al.* 2006 Evidence for subcomplexes in the Fanconi anemia pathway. *Blood* **108**, 2072–2080. (doi:10.1182/blood-2005-11-008151)
135. Yamamoto KN, Kobayashi S, Tsuda M, Kurumizaka H, Takata M, Kono K, Jiricny J, Takeda S, Hirota K. 2011 Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. *Proc. Natl Acad. Sci. USA* **108**, 6492–6496. (doi:10.1073/pnas.1018487108%J)
136. Swuec P, Renault L, Borg A, Shah F, Murphy VJ, van Twest S, Snijders AP, Deans AJ, Costa A. 2017 The FA core complex contains a homo-dimeric catalytic module for the symmetric mono-ubiquitination of FANCI-FANCD2. *Cell Rep.* **18**, 611–623. (doi:10.1016/j.celrep.2016.11.013)
137. van Twest S, Murphy VJ, Hodson C, Tan W, Swuec P, O'Rourke JJ, Heierhorst J, Crismani W, Deans AJ. 2017 Mechanism of ubiquitination and deubiquitination in the fanconi anemia pathway. *Mol. Cell* **65**, 247–259. (doi:10.1016/j.molcel.2016.11.005)
138. Tan W, van Twest S, Leis A, Bythell-Douglas R, Murphy VJ, Sharp M, Parker MW, Crismani W, Deans AJ. 2020 Monoubiquitination by the human Fanconi anemia core complex clamps FANCI:FANCD2 on DNA in filamentous arrays. *eLife* **9**, e54128. (doi:10.7554/eLife.54128)
139. Pan X, Drosopoulos WC, Sethi L, Madireddy A, Schildkraut CL, Zhang D. 2017 FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. *Proc. Natl Acad. Sci. USA* **114**, E5940–E5949. (doi:10.1073/pnas.1708065114)
140. Lu R *et al.* 2019 The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT). *Nat. Commun.* **10**, 2252. (doi:10.1038/s41467-019-10180-6)
141. Poole LA, Cortez D. 2017 Functions of SMARCAL1, ZRANB3, and HLF1 in maintaining genome stability. *Crit. Rev. Biochem. Mol. Biol.* **52**, 696–714. (doi:10.1080/10409238.2017.1380597)
142. Poole LA, Zhao R, Glick GG, Lovejoy CA, Eischen CM, Cortez D. 2015 SMARCAL1 maintains telomere integrity during DNA replication. *Proc. Natl Acad. Sci. USA* **112**, 14 864–14 869. (doi:10.1073/pnas.1510750112)
143. Cox KE, Marechal A, Flynn RL. 2016 SMARCAL1 resolves replication stress at ALT telomeres. *Cell Rep.* **14**, 1032–1040. (doi:10.1016/j.celrep.2016.01.011)
144. Betous R, Couch FB, Mason AC, Eichman BF, Manosas M, Cortez D. 2013 Substrate-selective repair and restart of replication forks by DNA translocases. *Cell Rep.* **3**, 1958–1969. (doi:10.1016/j.celrep.2013.05.002)
145. O'Rourke JJ, Bythell-Douglas R, Dunn EA, Deans AJ. 2019 ALT control, delete: FANCM as an anti-cancer target in Alternative Lengthening of Telomeres. *Nucleus* **10**, 221–230.
146. Jiao AL, Perales R, Umbreit NT, Haswell JR, Piper ME, Adams BD, Pellman D, Kennedy S, Slack FJ. 2019 Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factor. *RNA* **25**, 352–363. (doi:10.1261/ma.069773.118)
147. Richard P, Ogami K, Chen Y, Feng S, Moresco JJ, Yates JR, 3rd, Manley JL. 2018 NRDE-2, the human homolog of fission yeast Nrl1, prevents DNA damage accumulation in human cells. *RNA Biol.* **15**, 868–876. (doi:10.1080/15476286.2018.1467180)
148. Sneddon AA, Wu HC, Farquharson A, Grant I, Arthur JR, Rotondo D, Choe SN, Wahle KW. 2003 Regulation of selenoprotein GPx4 expression and activity in human endothelial cells by fatty acids, cytokines and antioxidants. *Atherosclerosis* **171**, 57–65. (doi:10.1016/j.atherosclerosis.2003.08.008)
149. Loeser H *et al.* 2020 Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. *Sci. Rep.* **10**, 18411. (doi:10.1038/s41598-020-75085-7)
150. Bogatyrova O *et al.* 2021 FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. *Euro. J. Cancer* **151**, 136–149. (doi:10.1016/j.ejca.2021.04.005)
151. Yu L, Ma H, Ji X, Volkert MR. 2016 The Sub1 nuclear protein protects DNA from oxidative damage. *Mol. Cell Biochem.* **412**, 165–171. (doi:10.1007/s11010-015-2621-x)
152. Ge H, Roeder RG. 1994 Purification, cloning, and characterization of a human coactivator, PC4, that mediates transcriptional activation of class II genes. *Cell* **78**, 513–523. (doi:10.1016/0092-8674(94)90428-6)
153. Tan I, Ng CH, Lim L, Leung T. 2001 Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. *J. Biol. Chem.* **276**, 21 209–21 216. (doi:10.1074/jbc.M102615200)
154. Yam CH, Fung TK, Poon RYC. 2002 Cyclin A in cell cycle control and cancer. *Cell. Mol. Life Sci.* **59**, 1317–1326. (doi:10.1007/s00018-002-8510-y)
155. MacKenzie D *et al.* 2021 ALT Positivity in human cancers: prevalence and clinical insights. *Cancers* **13**, 2384. (doi:10.3390/cancers13102384)